0 192

Cited 90 times in

Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in type 2 diabetes

Authors
 Eun Seok Kang  ;  So Young Park  ;  Hyeong Jin Kim  ;  Chul Sik Kim  ;  Chul Woo Ahn  ;  Bong Soo Cha  ;  Sung Kil Lim  ;  Chung Mo Nam  ;  Hyun Chul Lee 
Citation
 CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.78(2) : 202-208, 2005 
Journal Title
 CLINICAL PHARMACOLOGY & THERAPEUTICS 
ISSN
 0009-9236 
Issue Date
2005
MeSH
Adult ; Aged ; Aged, 80 and over ; Diabetes Mellitus, Type 2/genetics* ; Female ; Humans ; Hypoglycemic Agents/pharmacology* ; Male ; Middle Aged ; PPAR gamma/drug effects* ; Polymorphism, Genetic ; Rosiglitazone ; Thiazolidinediones/pharmacology*
Keywords
16084854
Abstract
OBJECTIVE: The aim of this study was to examine the effects of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor (PPAR) gamma2 gene on the response to rosiglitazone in patients with type 2 diabetes mellitus. METHODS: A total of 198 patients with type 2 diabetes mellitus were treated with rosiglitazone (4 mg/d) for 12 weeks without a change in previous medications. All patients were genotyped for the PPARgamma2 Pro12Ala polymorphism. RESULTS: The Ala12 allele frequency was 0.04. Of the 198 patients, 183 had the Pro12Pro genotype and 15 had the Pro12Ala genotype. The Ala12Ala genotype was not observed. The decrease in fasting plasma glucose level was significantly greater in subjects with the Ala12 allele than in those without the allele (50.6 +/- 27.8 mg/dL versus 24.3 +/- 41.9 mg/dL, P = .026). In addition, the decrease in hemoglobin A(1c) level was significantly greater in subjects with the Ala12 allele than in those without the allele (1.41% +/- 1.47% versus 0.57% +/- 1.16%, P = .015). There was a significant difference in the response rate to rosiglitazone treatment between the Pro12Pro group and the Pro12Ala variant group (43.72% versus 86.67%, P = .002). CONCLUSION: Patients with the Pro12Ala genotype in the PPARgamma2 gene had a better therapeutic response to rosiglitazone than did patients with the Pro12Pro genotype. The genetic variations in the PPARgamma2 gene can affect the response to rosiglitazone treatment in patients with type 2 diabetes mellitus.
Full Text
http://www.nature.com/clpt/journal/v78/n2/full/clpt2005484a.html
DOI
10.1016/j.clpt.2005.04.013
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Preventive Medicine and Public Health (예방의학교실) > 1. Journal Papers
Yonsei Authors
Kang, Eun Seok(강은석) ORCID logo https://orcid.org/0000-0002-0364-4675
Kim, Chul Sik(김철식)
Kim, Hyeong Jin(김형진)
Nam, Jung Mo(남정모) ORCID logo https://orcid.org/0000-0003-0985-0928
Park, So Young(박소영)
Ahn, Chul Woo(안철우) ORCID logo https://orcid.org/0000-0003-3733-7486
Lee, Hyun Chul(이현철)
Lim, Sung Kil(임승길)
Cha, Bong Soo(차봉수) ORCID logo https://orcid.org/0000-0003-0542-2854
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/147591
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse